Skip to content

US · ADVB · MEDICAL - DIAGNOSTICS & RESEARCH

Advanced Biomed Inc. Common Stock (ADVB) intrinsic value and stock valuation

$1.65as of 2026-11-21 · Mkt cap 8.8M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Advanced Biomed Inc. Common Stock DCF and intrinsic value

InvestorsCraft values ADVB with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ADVB’s statements →

Advanced Biomed Inc. Common Stock Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Diagnostics & Research New York City, NY 10168 advanbiomed.com

How the business is doing

Fiscal 2021–2025, USD

Revenue
$0.00
20212025
Net income
-$-100K
20212025
Free cash flow
-$-180K
20212025
Total equity
$3.48M
20212025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2021–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-90K-$-2.54M-$-100K-$-2.37M-$-1.84M
Net income-$-100K-$-2.78M-$-120K-$-4.03M-$-1.84M
EPSd-$-92.59K-$-2.57M-$-111.11K-$-3.73M-$-1.7M
Operating cash flow-$-180K-$-2.13M-$-2.96M-$-740K-$-470K
Capital expenditure-$0.00-$-70K-$-210K-$-1.31M-$-30K
Free cash flow-$-180K-$-2.2M-$-3.18M-$-2.05M-$-500K
Total assets$6.51M$4.46M$4.6M$6.71M$1.01M
Total debt$1.26M$130K$240K$480K$10K
Net debt-$-1.64M-$-2.48M-$-2.38M-$-4.31M-$-60K
Total equity$3.48M$1.66M$1.31M$3.49M$980K
Cash and short-term investments$2.9M$2.61M$2.62M$4.78M$70K
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$10K$0.00$10K$0.00$0.00
Gross profit-$-10K$0.00-$-10K$0.00$0.00
Research and development expenses$30K$880K$50K$1.62M$1.73M
Selling, general and administrative expenses$60K$1.26M$40K$620K$40K
Other expenses$0.00$400K$370K$130K$60K
Operating expenses$80K$2.54M$90K$2.37M$1.84M
Cost and expenses$90K$2.54M$100K$2.37M$1.84M
Interest income$0.00$50K$20K$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$10K$400K$10K$130K$60K
Ebitda-$-80K-$-2.14M-$-90K-$-2.24M-$-1.78M
Operating income-$-90K-$-2.54M-$-100K-$-2.37M-$-1.84M
Total other income/expenses, net-$-10K-$-240K-$-20K-$-1.65M-$0.00
Income before tax-$-100K-$-2.78M-$-120K-$-4.03M-$-1.84M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-100K-$-2.78M-$-120K-$-4.03M-$-1.84M
Weighted average shares outstanding$1.08M$1.08M$1.08M$1.08M$1.08M
Weighted average diluted shares outstanding$1.08M$1.08M$1.08M$1.08M$1.08M
Balance sheet
20252024202320222021
Cash and short-term investments$2.9M$2.61M$2.62M$4.78M$70K
Net receivables$10K$10K$0.00$160K$0.00
Inventory$0.00-$-10K$0.00$0.00$0.00
Total current assets$6.03M$3.05M$2.79M$5.01M$910K
Property, plant and equipment, net$65.4M$650K$950K$1.23M$90K
Goodwill and intangible assets$0.00$120K$250K$410K$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$480K$1.41M$1.81M$1.71M$90K
Total assets$6.51M$4.46M$4.6M$6.71M$1.01M
Accounts payable$20K$620K$630K$760K$0.00
Short-term debt$1.12M$60K$220K$240K$10K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$2.89M$2.73M$3.28M$2.99M$30K
Long-term debt$140K$60K$20K$230K$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$150K$60K$20K$230K$0.00
Capital lease obligations$40K$130K$240K$470K$10K
Total liabilities$3.03M$2.8M$3.29M$3.22M$30K
Common stock$20K$20K$20K$100K$10K
Retained earnings-$-19.23M-$-15.97M-$-13.19M-$-9.46M-$-5.43M
Accumulated other comprehensive income (loss)$1.34M$1.12M$800K$270K-$-180K
Total equity$3.48M$1.66M$1.31M$3.49M$980K
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$1.26M$130K$240K$480K$10K
Net debt-$-1.64M-$-2.48M-$-2.38M-$-4.31M-$-60K
Cash flow statement
20252024202320222021
Net income-$-100K-$-2.78M-$-3.73M-$-4.03M-$-1.84M
Depreciation and amortization$10K$400K$370K$130K$60K
Stock-based compensation$0.00$0.00$0.00$0.00$0.00
Change in working capital-$-90K$260K$250K$1.5M$1.31M
Accounts receivable$0.00$50K$20K$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$0.00$480K$380K$910K$20K
Net cash provided by operating activities-$-180K-$-2.13M-$-2.96M-$-740K-$-470K
Investments in property, plant and equipment-$0.00-$-70K-$-210K-$-890K-$-30K
Acquisitions, net$0.00$0.00-$-50K$200K$0.00
Net cash used for investing activities-$0.00-$-70K-$-260K-$-1.08M-$-30K
Common stock issued$170K-$0.00$1.01M$6.1M$700K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$180K$1.87M$460K$6.1M$700K
Net change in cash$20K-$-10K-$-2.16M$4.72M$0.00
Cash at end of period$100K$2.61M$2.62M$4.78M$70K
Operating cash flow-$-180K-$-2.13M-$-2.96M-$-740K-$-470K
Capital expenditure-$0.00-$-70K-$-210K-$-1.31M-$-30K
Free cash flow-$-180K-$-2.2M-$-3.18M-$-2.05M-$-500K
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Advanced Biomed Inc. Common Stock

        Advanced Biomed Inc. functions as an investment holding company, primarily dedicated to the research and development of microfluidic biochip technologies. Based in Taiwan, the company leverages these innovations to enhance precision oncology, spanning cancer detection, diagnosis, and treatment. Its diverse product portfolio includes a suite of advanced devices: A+Pre: A fully automated system designed for pre-concentrating diluted blood samples. AC-1000: A rare cell device engineered to address the challenges of detecting cells in hypercoagulable samples from tumor patients. A+SCDrop: A specialized tool for capturing individual circulating tumor cells (CTCs). A+CellScan: An analyzer featuring an immunostaining chip, utilized for the immunostaining and analysis of output from the AC-1000. Beyond standalone devices, Advanced Biomed provides microfluidic biochips, including the A+Pre, AC-1000 CTC Enrichment, and A+CellScan chips, which are integral to delivering assay products and services to cancer patients. The company also offers a comprehensive range of immunochromogenic kits: A+CTCE kit: Used to identify epithelial circulating tumor cells by detecting EpCAM, CK (pan), CD45, and CD14 antibodies. A+CTCM kit: Targets mesenchymal circulating tumor cells through their expression of Vimentin, CD45, and CD14 antibodies. A+EMT kit: Designed for the identification of epithelial-to-mesenchymal circulating tumor cells, focusing on cell-surface Vimentin, CD45, and CD14 antibodies. A+CM kit: Facilitates the detection of tumor-associated macrophages by assessing PD-L1, CD45, and CD14 antibodies. In addition to its current offerings, Advanced Biomed is actively developing A+LCGuard, a promising solution for the early screening of lung cancer. The company further expands its presence by establishing and operating medical clinics in the People's Republic of China. Founded in 2014, Advanced Biomed Inc. maintains its corporate headquarters in New York, New York.

        CEO
        Xiaomin Chen
        Employees
        31
        Beta
        -0.36

        Explore

        Frequently asked questions

        What is the intrinsic value of Advanced Biomed Inc. Common Stock (ADVB)?

        InvestorsCraft does not currently publish an intrinsic value for ADVB. How the IC value is calculated.

        Is ADVB undervalued?

        InvestorsCraft does not publish an undervaluation signal for ADVB at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.